1. Introduction
===============

Myostatin, a member of the transforming growth factor-β superfamily and also known as growth factor and differentiation factor-8 (GDF-8), is an essential muscle endogenous negative regulatory factor secreted by skeletal muscles. Myostatin is mainly expressed in skeletal muscle tissue and negatively regulates muscle growth and development \[[@B1-ijms-16-07976],[@B2-ijms-16-07976]\]. In 1997, MSTN was first confirmed as a muscle growth inhibitor in a knockout mouse model. As reported, the muscles of the myostatin-null mice weighed almost two times as much as those of the controls due to increased muscle fiber number and diameter \[[@B3-ijms-16-07976],[@B4-ijms-16-07976],[@B5-ijms-16-07976]\]. Myostatin was highly conserved, and it can inhibit muscle growth in other mammalian species. The mutation and inhibition of MSTN can dramatically increase muscle mass in most mammal species. A natural mutation of myostatin in double-muscled cattle may account for the double muscling phenotype \[[@B6-ijms-16-07976],[@B7-ijms-16-07976]\]. A genetic study confirmed that one G/A mutation identified in the 3\' UTR of the myostatin gene formed a novel binding site for miR-1 and miR-206 in Texel sheep. These miRNAs inhibited the protein expression of MSTN, causing the muscle hypertrophy phenomenon in this sheep breed \[[@B8-ijms-16-07976]\]. Furthermore, a mutant MSTN gene causes muscle hypertrophy in humans \[[@B9-ijms-16-07976]\].

MSTN is synthesized as an inactive precursor protein, which is the predominant form in the muscle extracellular matrix and in circulation \[[@B10-ijms-16-07976]\]. The precursor protein undergoes dimerization and two proteolytic cleavage processes to generate a *C*-terminal dimer---an active biological molecule. The dimer remains in an inactive, latent complex with the *N*-terminal pro-peptide and circulates in the blood \[[@B5-ijms-16-07976]\]. The *C*-terminal dimer (mature myostatin) can be activated when separated with the *N*-terminal, and mature myostatin can bind to the transmembrane ActRIIA/B receptor, which then recruits the type I receptor, ALK-4/5, and phosphorylates the type I receptor to activate its kinase domains \[[@B11-ijms-16-07976],[@B12-ijms-16-07976],[@B13-ijms-16-07976]\]. After binding the receptors, Smad2 and Smad3 can be activated to form a heterodimer complex with Smad4. The Smad complex then activates the Erk1/2 MAPK pathway, which can prevent the proliferation of myoblasts via the p21/Rb signaling cascade pathway and can promote anti-apoptotic pathways by activating p53 in differentiated cells. Moreover, activated Smad3 can repress the level of the muscle regulatory factors (MRFs) \[[@B14-ijms-16-07976]\]. During the interference of Smad3, MyoD sequesters in the cytoplasm and does not enter the nucleus to activate myogenesis \[[@B15-ijms-16-07976]\]. The activated Smad complex can activate Smad4 and cause it to translocate to the nucleus to block the transactivation of MyoD and activate the expression of Smad7 \[[@B11-ijms-16-07976],[@B16-ijms-16-07976],[@B17-ijms-16-07976]\]. Furthermore, phosphorylated SMAD3 can inhibit the PI3K/Akt/mTOR signaling pathway via the induction of E3-ligase atrogin-1 \[[@B18-ijms-16-07976],[@B19-ijms-16-07976]\]. A previous study also found that MSTN can induce muscle protein degradation by activating the ubiquitin-proteasome to inhibit the PI3K/Akt/mTOR signaling pathway \[[@B20-ijms-16-07976]\].

Blocking the myostatin signaling transduction pathway can induce a highly muscled phenotype \[[@B21-ijms-16-07976]\]. The ability of several myostatin antagonists, such as follistatin, follistatin-related gene, soluble activin receptor IIB and suramin to block MSTN signaling transduction has been tested \[[@B22-ijms-16-07976],[@B23-ijms-16-07976],[@B24-ijms-16-07976],[@B25-ijms-16-07976]\]. Furthermore, some microRNAs can affect the MSTN signaling pathway by targeting the 3\' UTR of myostatin \[[@B26-ijms-16-07976],[@B27-ijms-16-07976]\]. We previously generated transgenic mice via the muscle-specific expression of a cDNA sequence (5\'-region 886 nucleotides) encoding the MSTN propeptide. The transgene effectively depressed myostatin function, and transgenic mice showed dramatic growth and increases in muscle mass due to muscle fiber hypertrophy \[[@B28-ijms-16-07976],[@B29-ijms-16-07976],[@B30-ijms-16-07976]\]. To further elucidate the mechanisms of muscle hypertrophy caused by MSTN inhibition, we compared the gene expression profiles of the muscle tissue between MSTN propeptide transgenic mice and their littermate wild-type controls. Our results indicate that the Ky/mybph/actins pathway is a novel noncanonical signaling pathway, and phosphatidic acid inhibits mTOR signaling via Dgki, Dgkz and Plcd4 in the hypertrophic skeletal muscle of the MSTN propeptide transgenic mice.

2. Results
==========

2.1. Skeletal Muscle Weights of the Transgenic Mice and Wild-Type Littermate Controls
-------------------------------------------------------------------------------------

The mice were sacrificed at four months of age to evaluate the muscle weight and obtain muscle samples. The results were consistent with our previous report; the individual major muscles of the myostatin propeptide transgenic mice were significantly heavier (38% to 95% more muscle) than those of the wild-type littermate controls ([Figure 1](#ijms-16-07976-f001){ref-type="fig"}). The muscle groups that increased in mass predominantly consisted of fast-twitch muscle fibers, including the gastrocnemius, tibialis anterior, biceps femoris, triceps brachii, longissimus dorsi, and semitendinosus.

![The skeletal muscle weights of the transgenic mice and wild-type littermate controls.](ijms-16-07976-g001){#ijms-16-07976-f001}

2.2. Solexa Sequencing Data and Reads Assembly Using Tophat Software
--------------------------------------------------------------------

In this study, Solexa sequencing was used to detect the mRNA expression profiles of MSTN propeptide transgenic mice and their littermates. Five RNA libraries were constructed from the total RNA isolated from the gastrocnemius muscle of the transgenic and control mice, which generated 9,710,772 (CN148), 10,371,693 (CN164), 9,991,395 (TN126), 10,258,517 (TN135), and 10,076,991 (TN329) raw reads. After filtering the low quality reads and trimming off the adapted fragments, 8,717,967, 9,418,459, 9,054,439, 9,301,124, and 9,032,266 clean reads were obtained, and the ratios of cleans reads in raw reads were 89.78%, 90.81%, 90.62%, 90.67%, and 89.63% ([Table 1](#ijms-16-07976-t001){ref-type="table"}). The detailed description of the sequence data is shown in [Table 1](#ijms-16-07976-t001){ref-type="table"}, and the abundance of mRNA reads mapped to each chromosome is shown in [Figure S1](#app1-ijms-16-07976){ref-type="app"}. The Tophat aligner software was used to align the sequencing reads to the reference genome download from the ENSEMBEL website <ftp://ftp.ensembl.org/pub/release-75/fasta/mus_musculus/dna/.> The mapping rate of each sample exceeded 97% ([Table 2](#ijms-16-07976-t002){ref-type="table"}). The statistical alignment data indicated that the sequencing reads were of high quality and the sequencing depth was sufficient for a differential expression analysis between the two groups. Subsequently, HTSeq was selected to control the quality of aligned reads. The quality control result is shown in [Figure S2](#app1-ijms-16-07976){ref-type="app"}.
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###### 

The overview of raw RNA sequencing data in muscle samples of propeptide transgenic and control mice.

                CN148       CN164        TN126       TN135        TN329
  ------------- ----------- ------------ ----------- ------------ ------------
  Raw reads     9,710,772   10,371,693   9,991,395   10,258,517   10,076,991
  Clean reads   8,717,967   9,418,459    9,054,439   9,301,124    9,032,266
  Ratio         89.78%      90.81%       90.62%      90.67%       89.63%
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###### 

The clean reads counts and alignment results of each library.

                         CN148       CN164       TN126       TN135       TN329
  ---------------------- ----------- ----------- ----------- ----------- -----------
  Input                  8,717,967   9,418,459   9,054,439   9,301,124   9,032,266
  Output                 8,717,523   9,418,247   9,054,198   9,300,876   9,031,776
  Qualified              99.99%      99.99%      99.99%      99.99%      99.99%
  Mapped                 8,583,223   9,251,338   8,865,832   9,118,889   8,890,164
  Mapped%                98.5%       98.2%       97.9%       98%         98.4%
  Multiple alignments    2,249,697   1,869,472   1,801,533   1,789,715   2,407,543
  Multiple alignments%   26.2%       20.2%       20.3%       19.6%       27.1%
  Min read length        30          30          30          30          30
  Max read length        50          50          50          50          50

2.3. Differentially Expressed Genes of Skeletal Muscle between Transgenic Mice and Their Littermate Controls
------------------------------------------------------------------------------------------------------------

The cufflinks software was used to assemble the individual transcripts that had been aligned to the genome and quantify the expression level of each transfrag in the sample. After cufflinks treated the reads, cuffmerge was used to parsimoniously merge the assembled transfrags. The annotation reference file of Mus musculus integrated into the merged assembly was downloaded from ENSEMBEL (<ftp://ftp.ensembl.org/pub/release-75/gtf/mus_musculus/>) \[[@B31-ijms-16-07976]\]. Cuffdiff was used to calculate the differential expression and analyze the significances of observed changes between two groups. A cluster analysis was performed to elaborate the expression patterns of genes in MSTN propeptide transgenic mice and their controls ([Figure 2](#ijms-16-07976-f002){ref-type="fig"}A). The results showed that approximately 70% genes were up-regulated in the transgenic mice. CummeRbund volcano plots ([Figure 2](#ijms-16-07976-f002){ref-type="fig"}B) were available to intuitively observe the genes that were differentially expressed between the two groups. Finally, the expression levels of 132 genes were identified to be significantly different between the transgenic mice and control mice; among these genes, 97 were up-regulated and 35 were down-regulated (FDR \< 0.05). Of the 132 genes, 117 were annotated in the database. The differentially expressed genes with more than two-fold changes and an FPKM value more than 5 are listed in [Table 3](#ijms-16-07976-t003){ref-type="table"}. Several genes have not been reported to be involved in skeletal muscle hypertrophy, including myosin binding protein H (mybph), beta, gamma and alpha actin (Actb, actc1, actg1), protein tyrosine phosphatase receptor type c (Ptprc), zinc metallopeptidase STE24 (zmpste24), and genes related to phosphatidic acid (PA) pathways (Dgki, Dgkz and Plcd4). Moreover, the gene kyphoscoliosis peptidase (Ky), which plays an important role in muscle growth, was also up-regulated in the skeletal muscle of the transgenic mice. The bar plots of the differentially expressed genes are shown in [Figure S3](#app1-ijms-16-07976){ref-type="app"}, and all differentially expressed genes identified by RNA-seq are summarized in [Table S1](#app1-ijms-16-07976){ref-type="app"}.

![Differentially expressed genes between MSTN propeptide transgenic mice and their littermate control mice. (**A**) A heatmap of FPKM expression values in the five samples. Each row represents a gene ID and the column represents a sample; (**B**) The volcano plots reveal genes that differ significantly between two groups. The black dots represent the expression levels of genes that do not differ and the red dots represent the expression level differences.](ijms-16-07976-g002){#ijms-16-07976-f002}
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###### 

Differentially expressed genes between myostatin propeptide transgenic and littermate control mice. (FPKM ≥ 5; fold change ≥ 2). inf represent the fold change cannot be calculated because the expression level was not detectable in wild-type mice.

  Gene ID                                                                                  Gene       Official Full Name                                                       CN Value   TN Value   Fold Change   *p*-Value
  ---------------------------------------------------------------------------------------- ---------- ------------------------------------------------------------------------ ---------- ---------- ------------- -----------
  **Genes Related to Cytoskeleton and Muscle Development**                                                                                                                                                         
  XLOC_010673                                                                              Myh6       Myosin heavy polypeptide 6                                               5.49       0.70       −7.83         0.00010
  XLOC_000666                                                                              Mybph      Myosin binding protein H                                                 14.77      57.60      3.90          0.00005
  XLOC_003363                                                                              Rmst       Rhabdomyosarcoma 2 associated transcript                                 0.53       15.11      28.72         0.00005
  XLOC_006460                                                                              Actg1      Actin gamma cytoplasmic 1                                                11.26      355.42     31.56         0.00005
  XLOC_019664                                                                              Actc1      Actin alpha cardiac muscle 1                                             50.30      257.64     5.12          0.00005
  XLOC_034484                                                                              Ky         Kyphoscoliosis peptidase (CD1)                                           3.26       8.81       2.70          0.00015
  XLOC_026810                                                                              Actb       Actin beta                                                               26.24      67.11      2.56          0.00020
  XLOC_000205                                                                              Mstn-pro   Myostatin propeptide                                                     32.03      409.35     12.78         0.00005
  **Genes Related to Lipoprotein Metabolic Process and Intracellular Signaling Cascade**                                                                                                                           
  XLOC_034105                                                                              Apoa1      Apolipoprotein A-I                                                       11.04      1.76       −6.27         0.00025
  XLOC_019500                                                                              Dgkz       Diacylglycerol kinase zeta                                               22.14      90.10      4.07          0.00025
  XLOC_000353                                                                              Plcd4      Phospholipase C delta 4                                                  3.76       17.38      4.63          0.00010
  XLOC_025320                                                                              Alb        Albumin                                                                  83.44      9.80       −8.51         0.00005
  XLOC_002012                                                                              G0s2       G0/G1 switch gene 2                                                      4.35       23.62      5.42          0.00005
  **Genes for Immune Response**                                                                                                                                                                                    
  XLOC_007714                                                                              Ighm       Immunoglobulin heavy constant mu                                         27.24      73.44      2.70          0.00020
  XLOC_007114                                                                              Tnfaip2    Tumor necrosis factor alpha-induced protein 2                            3.90       17.93      4.60          0.00010
  XLOC_031749                                                                              Trim12c    Tripartite motif-containing 12C                                          0.34       34.88      103.84        0.00025
  **Genes for Oxidation Reduction**                                                                                                                                                                                
  XLOC_006482                                                                              Cbr2       Carbonyl reductase 2                                                     4.44       41.62      9.37          0.00010
  XLOC_010336                                                                              Mss51      Mitochondrial translational activator                                    77.38      16.04      −4.83         0.00005
  XLOC_020605                                                                              Kcnab1     Potassium voltage-gated channel shaker-related Subfamily beta member 1   2.86       11.06      3.87          0.00020
  **Genes for Cell Proliferation**                                                                                                                                                                                 
  XLOC_001651                                                                              Ptprc      Protein tyrosine phosphatase receptor type C (CD45)                      0.81       7.90       9.77          0.00005
  XLOC_026557                                                                              Gm13841    Predicted gene 13841 (ribosomal protein L29)                             0.00       8.32       inf           0.00005
  **Genes of Proteolysis**                                                                                                                                                                                         
  XLOC_024383                                                                              Zmpste24   Zinc metallopeptidase STE24                                              5.67       27.67      4.88          0.00015
  **Genes of Carbohydrate Phosphatase Activity**                                                                                                                                                                   
  XLOC_018711                                                                              Pfkfb3     6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3                    8.83       30.52      3.46          0.00005
  **Genes of Integral to Membrane, Intrinsic to Membrane**                                                                                                                                                         
  XLOC_015439                                                                              Aqp4       Aquaporin 4                                                              2.40       6.81       2.83          0.00020
  **Genes of Extracellular Region**                                                                                                                                                                                
  XLOC_025292                                                                              Csn1s2a    casein alpha s2-like A                                                   0.00       8.54       inf           0.00005
  **Others**                                                                                                                                                                                                       
  XLOC_029580                                                                              Josd2      Josephin domain containing 2                                             109.35     22.64      −4.83         0.00005
  XLOC_025924                                                                              Gm15459    Predicted gene 15459 (heat shock protein 8 pseudogene)                   7.46       21.77      2.92          0.00005
  XLOC_003234                                                                              Odf3l2     Outer dense fiber of sperm tails 3-like 2                                14.39      57.11      3.97          0.00005

2.4. Function Annotation of the Differentially Expressed Genes
--------------------------------------------------------------

To gain insight into the function of the differentially expressed genes in the hypertrophic skeletal muscle of the MSTN propeptide transgenic mice, the DAVID (Database for Annotation, Visualization and Integrated Discovery) website (<http://david.abcc.ncifcrf.gov/>) was used to identify the gene function with the following parameters: Count = 2 and EASE = 0.01. The gene ontology functional classification is shown in [Figure 3](#ijms-16-07976-f003){ref-type="fig"}. The functions of genes in biological processes, cellular components and molecular processes were annotated based on the GO categories. Most genes were enriched in two types of cellular components: the extracellular region and extracellular space. The genes enriched in biological processes were mainly involved in biological adhesion and cell adhesion. The genes enriched in molecular function were mainly associated with calcium ion binding.

![Overview of enriched gene ontology functional classifications of muscle differential expression genes between MSTN propeptide transgenic and wild-type mice.](ijms-16-07976-g003){#ijms-16-07976-f003}

2.5. Validation of the Differentially Expressed Genes by RT-qPCR
----------------------------------------------------------------

To verify the reliability of the sequencing data, five genes were randomly selected from [Table 3](#ijms-16-07976-t003){ref-type="table"} for RT-qPCR analyses ([Figure 4](#ijms-16-07976-f004){ref-type="fig"}). As expected, the gene expression patterns validated by RT-qPCR strongly correlated with the sequencing results (Pearson's r correlation coefficient is 0.97591, [Figure 5](#ijms-16-07976-f005){ref-type="fig"}). Both RT-qPCR and solexa sequencing indicated that MSTN propeptide, Cbr2, Tnfaip2 and Mybph were up-regulated, while Mss51 was down-regulated in MSTN propeptide transgenic mice. Among the differentially expressed genes, the MSTN propeptide mRNA level increased by 12.78-fold according to solexa sequencing ([Figure S4](#app1-ijms-16-07976){ref-type="app"}) and 43-fold according to the RT-qPCR analyses ([Figure 4](#ijms-16-07976-f004){ref-type="fig"}A). We also detected the expression level of endogenous MSTN; the endogenous myostatin expression did not significantly differ (*p* \> 0.05) between the transgenic mice and their littermate wild-type controls ([Figure 4](#ijms-16-07976-f004){ref-type="fig"}B).

![Q-PCR validation of genes from RNA-seq results between MSTN propeptide transgenic and control mice. All samples were normalized to 18S RNA. (**A**) Tnfaip2, Mybph, Cbr2 and MSTN propeptide were highly expressed in transgenic mice (TN) compared with control mice (CN). Mss51 had lower expression in transgenic mice (TN) compared with control mice (CN); (**B**) Endogenous myostatin (*C*-terminal mature peptide) mRNA levels in transgenic mice was slightly higher than the controls, but not significantly different from the control (*p* \> 0.05). The error bars show the SD. Two-tailed *t*-test was used to calculate the significance of differentially expressed genes. Mark \* in [Figure 4](#ijms-16-07976-f004){ref-type="fig"}A represent the expression level significantly different between two group (*p* \< 0.05).](ijms-16-07976-g004){#ijms-16-07976-f004}

![Line fit plot of Q-PCR results and RNA-Seq data for selected genes difference expression between MSTN propeptide transgenic and control mice. Linear regression model and *R*-Squared shown in the figure.](ijms-16-07976-g005){#ijms-16-07976-f005}

2.6. Signaling Pathway Analysis
-------------------------------

To identify pathways that are involved in the regulation of muscle hypertrophy in the MSTN propeptide transgenic mice, we employed the DAVID website to analyze the differentially expressed genes with the following parameters: Count = 2 and EASE = 0.1. The pathways and related genes are listed in [Table 4](#ijms-16-07976-t004){ref-type="table"}. This analysis identified the hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy signaling pathways, both of which regulate muscle growth and development. In addition, pathways associated with the maintenance of muscle structure and myocytes were identified, including the ECM-receptor interaction and focal adhesion pathways. Notably, the gene expression of three key enzymes, Dgki, Dgkz and Plcd4, of the phosphatidic acid (PA) signaling system was significantly enhanced in the skeletal muscle of the transgenic mice compared with their littermate controls ([Figure 6](#ijms-16-07976-f006){ref-type="fig"}). The hematopoietic cell lineage genes Itga4, cd3d and cd5 were also identified.

ijms-16-07976-t004_Table 4

###### 

The pathways regulated by differentially expressed genes.

  Category       Term                                                     Gene Counts   Genes
  -------------- -------------------------------------------------------- ------------- ----------------------------------
  KEGG_PATHWAY   Hypertrophic cardiomyopathy (HCM)                        5             Actb, Itga4, Actg1, Myh6, Acta
  KEGG_PATHWAY   Dilated cardiomyopathy                                   5             Actb, Itga4, Actg1, Myh6, Acta
  KEGG_PATHWAY   Focal adhesion                                           5             Lama1, Lamc3, Actb, Itga4, Actg1
  KEGG_PATHWAY   Arrhythmogenic right ventricular cardiomyopathy (ARVC)   3             Actb, Itga4, Actg1
  KEGG_PATHWAY   Phosphatidic acid signaling system                       3             Dgki, Dgkz, Plcd4
  KEGG_PATHWAY   Complement and coagulation cascades                      3             C4bp, Proc, F12
  KEGG_PATHWAY   ECM-receptor interaction                                 3             Lama1, Lamc3, Itga4
  KEGG_PATHWAY   Hematopoietic cell lineage                               3             Itga4, Cd3d, Cd5

![A theoretical model of the negative regulation of the PA signal pathway by myostatin in skeletal muscle. Plcd4 can catalyze hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and DAG \[[@B32-ijms-16-07976],[@B33-ijms-16-07976],[@B34-ijms-16-07976]\]. Diacylglycerol (DAG) can then be phosphorylated by Dgkz to produce phosphatidic acid (PA). Subsequently, PA binds to the FKBP12-rapamycine binding (FRB) domain of mTOR to induce muscle fiber hypertrophy \[[@B35-ijms-16-07976],[@B36-ijms-16-07976]\].](ijms-16-07976-g006){#ijms-16-07976-f006}

3. Discussion
=============

High-throughput sequencing technologies are currently emerging as a powerful tool to initially elaborate the genetic mechanisms responsible for a phenotype. Previous studies have detected genes related to the hypertrophic muscle observed in myostatin propeptide transgenic mice by employing microarray analysis \[[@B30-ijms-16-07976]\]. The results identified 52 unique genes that are differentially expressed, and myostatin propeptide promotes adult muscle growth and maintenance by up-regulating the expression levels of myogenic regulatory factors and extracellular matrix components and down-regulating protein degradation-related genes as well as mitochondrial ATP synthesis-related genes \[[@B30-ijms-16-07976]\].

To further illustrate the molecular mechanism and identify potential regulatory genes associated with the muscle hypertrophy caused by myostatin inhibition, we employed RNA sequencing technologies to study differences in the expression patterns between MSTN propeptide transgenic mice and wild-type littermate control mice at four months of age; these mice were younger than those used in the microarray study. In the current study, 132 differentially expressed genes were identified in MSTN propeptide transgenic mice compared with control mice based on the RNA sequencing technology and Cufflinks analysis method. Among these 132 genes, most were up-regulated in transgenic mice, and only 35 genes were down-regulated. Functional annotation showed that these differentially expressed genes mainly correlated with muscle development, lipid metabolism, energy metabolism and the immune system. Intriguingly, both of the abovementioned studies revealed that the function of some differentially expressed genes involves the extracellular region. Additionally, pathway analysis found four pathways in both studies: focal adhesion, ECM-receptor interaction, the regulation of the actin cytoskeleton, and cardiac muscle contraction.

In the current study, we found that the expression levels of cytoskeletal and muscle growth and development-related genes were changed in the transgenic mice. Strikingly, Myh6 was down-regulated in the transgenic mice compared with the wild-type controls. A previous study showed that protein synthesis and muscle hypertrophy were enhanced when the expression of myh6 was repressed \[[@B37-ijms-16-07976],[@B38-ijms-16-07976],[@B39-ijms-16-07976]\], suggesting that myh6 is a negative regulator of muscle mass. This finding is consistent with our results, which showed that Myh6 expression was decreased in muscle hypertrophy mice. Moreover, a previous study reported that the mitochondria number, the ratio of mitochondrial DNA to nuclear DNA, and the level of oxidative enzymes used to synthetize ATP all decreased in myostatin-deficient muscle \[[@B40-ijms-16-07976]\]. Other studies showed that Myh6 had higher ATPase activity compared with other myosins \[[@B38-ijms-16-07976],[@B41-ijms-16-07976]\]. Thus, the energy metabolism of myostatin propeptide transgenic mice may decrease due to a decrease in the expression of Myh6, which reduces ATP consumption. Unlike Myh6, the muscle growth-related genes Ky, Actb, Mybph, Actc1, RMST and Actg1 were up-regulated in our study. Among these genes, Ky (kyphoscoliosis peptidase) plays a vital role in muscle growth; the absence of Ky protein leads to muscular dystrophy \[[@B42-ijms-16-07976],[@B43-ijms-16-07976]\]. A Ky mutation results in degenerative myopathy and loss of muscle hypertrophy responses \[[@B42-ijms-16-07976]\]. Ky protein can interact with myosin-binding protein and filamin C \[[@B44-ijms-16-07976]\]. Moreover, Myosin-binding protein H (Mybph) reportedly interacts with Rho kinase 2 (ROCK2) to affect the interaction of actin-myosin \[[@B45-ijms-16-07976],[@B46-ijms-16-07976],[@B47-ijms-16-07976]\]. Additionally, Actb, Actc1 and Actg1 are three types of actins that participate in the maintenance of the cytoskeleton \[[@B48-ijms-16-07976]\]. A functional analysis of these cytoskeletal and muscle development-related genes suggested that myostatin propeptide can enhance muscle mass via the Ky/Mybph/Actins pathway.

Lipids play a critical role in signal transduction; they often act as a secondary messenger to activate downstream pathways \[[@B49-ijms-16-07976]\]. We found that the overexpression of myostatin propeptide activated the phosphatidic acid (PA) signaling pathway, which generates signaling lipids and participates in the cell cycle and cell growth \[[@B50-ijms-16-07976],[@B51-ijms-16-07976]\]. In the current study, we found that Plcd4 and Dgkz, two key enzymes of the PA signaling pathway, were up-regulated in myostatin propeptide transgenic mice. This result suggested a connection between the myostatin signaling and PA signaling pathways. Plcd4 is a member of the delta class of phospholipase C enzymes. Phospholipase C enzymes can catalyze hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP~2~) to two intracellular secondary messengers, inositol 1,4,5-trisphosphate (IP~3~) and diacylglycerol (DAG) \[[@B32-ijms-16-07976]\]. Previous studies reported that DAG could be phosphorylated by Dgkz, and the phosphorylated DAG could be digested to phosphatidic acid (PA). PA can reportedly bind to mTOR to induce muscle fiber hypertrophy \[[@B52-ijms-16-07976],[@B53-ijms-16-07976],[@B54-ijms-16-07976],[@B55-ijms-16-07976],[@B56-ijms-16-07976]\]. Other studies reported that myostatin mediates myoblast differentiation and myotube hypertrophy by inhibiting Akt/mTOR/p70S6 protein signaling \[[@B18-ijms-16-07976],[@B20-ijms-16-07976],[@B57-ijms-16-07976]\]. Overall, we may infer that myostatin can negatively regulate the PA signing pathway to inhibit the mTOR signaling pathway ([Figure 4](#ijms-16-07976-f004){ref-type="fig"}). In addition to activating the mTOR signaling pathway, PA also activates p21-activated kinase 1 (PAK1) to initiate the release of RhoGDI from Rac1, and RhoGD1 subsequently changes the actin dynamics \[[@B58-ijms-16-07976]\].

In biology, redox reactions can frequently store and release biological energy by electron transfer processes. In our study, we found that heme-binding protein Mss51, which is related to redox reactions, was down-regulated in myostatin propeptide transgenic mice. In yeast, Mss51 can regulate the biogenesis of cytochrome c oxidase (COX), the terminal electron transport chain (ETC) oxidase, thereby controlling energy production \[[@B59-ijms-16-07976],[@B60-ijms-16-07976]\]. Previous studies showed that cytochrome c oxidase subunit VIc (Cox6c) expression is decreased in myostatin propeptide transgenic mice \[[@B30-ijms-16-07976]\]. Although we did not detect differential Cox6c expression in our study, the expression of its upstream gene, Mss51, was decreased. Thus, we can infer that myostatin may influence ATP synthesis via Mss51. In addition, the gene Cbr2, which participates in neutralizing excessive reactive oxygen species (ROS), is also regulated by myostatin propeptide \[[@B61-ijms-16-07976],[@B62-ijms-16-07976],[@B63-ijms-16-07976]\]. Myostatin induces the production of ROS, which decreases muscle mass by regulating antioxidant gene expression and mitochondrial biogenesis \[[@B64-ijms-16-07976],[@B65-ijms-16-07976],[@B66-ijms-16-07976]\]. In combination with our results, these findings suggest that myostatin leads to muscle dystrophy by negatively regulating Cbr2 to increase ROS.

4. Experimental Section
=======================

4.1. Muscle Tissue Sample Collections
-------------------------------------

Myostatin propeptide cDNA under the control of rat myosin light chain 1 (MLC1) with its enhancer, SV40 poly A signal sequence, was constructed and served as the transgene construct, and transgenic mice were generated by standard microinjection techniques as previously described \[[@B28-ijms-16-07976],[@B29-ijms-16-07976],[@B30-ijms-16-07976]\]. Male mice (hemizygous genotype for the transgene) from the high-expressing line were mated with B6SJL F1 wild-type females. The mice were housed in cages with a 12-h light/dark cycle, and the room temperature was maintained at 22 °C. The mice were weaned at four weeks of age and given free access to a standard diet (10% kcal fat, ME 3.85 kcal/g). All procedures and animal care were in accordance with the institution guidelines and approved by the Institutional Animal Care and Use Committee of the University of Hawaii, Honolulu, HI, USA. Male mice were sacrificed at four months of age after 8 h of fasting to sample and dissect the muscle tissue. Gastrocnemius muscle samples from both legs were immediately dissected from the carcass, quickly frozen in liquid nitrogen, and stored at −80 °C. Three transgenic male mice and two wild-type littermate male control samples were used for this study.

4.2. RNA Isolation and RNA Sequencing
-------------------------------------

Total RNA was extracted from freshly frozen muscle tissues using the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. A magnetic bead homogenizer was used to homogenize the tissue and TRIzol Reagent. The quality and concentration of RNA was detected by NanoDrop ND2000 (Thermo Fisher Scientific, Waltham, MA, USA) spectrophotometry and gel electrophoresis. Solexa sequencing was used to detect the differentially expressed genes in the gastrocnemius of the transgenic and control mice. Five cDNA libraries were constructed using the TruSeq Stranded Total RNA LT Sample Prep Kit (Illumina, Santiago, CA, USA). The library construction and solexa sequencing were performed by Genergy biological technology Limited company (Shanghai, China).

4.3. Quality Control for Raw Sequencing Data
--------------------------------------------

The raw sequencing data were in a FASTQ file, and the data with clean reads were obtained by trimming the adapter contaminants and filtering the low-quality reads. A quality control tool, HTSeq (<https://pypi.python.org/pypi/HTSeq>), which can provide a quick impression of high throughput data, was utilized in our study. The quality control results are presented in the supplementary information.

4.4. Bioinformatics Analysis
----------------------------

The software Bowtie2 (<http://bowtie-bio.sourceforge.net/index.shtml/>) was used to merge the chromosome genomes of Mus musculus downloaded from the ENSEMBL database (<ftp://ftp.ensembl.org/pub/release-75/fasta/mus_musculus/dna/>) and convert them to the FM index, which can store massive genomic data and rapidly be searched. Tophat (<http://ccb.jhu.edu/software/tophat/index.shtml>), which uses Bowtie as an engine to align the sequencing reads to reference genome, was used to align the clean reads of each individual to the large genomes. Subsequently, the transcriptome was assembled with the Cufflinks software (<http://cufflinks.cbcb.umd.edu/>), and these assemblies were merged using Cuffmerge in the presence of the reference genome annotation (<ftp://ftp.ensembl.org/pub/release-75/gtf/mus_musculus/>). Cuffmerge provided a uniform basis to calculate the expression level of transcripts and genes at different conditions.

Cuffdiff, a separate program contained in Cufflink, was used to calculate the expression level of each individual and test the statistical significance between transgenic and control mice. Cuffdiff used FPKM (fragments per kilobase of transcript per million mapped fragments) method to calculate the expression level. In addition, CummeRbund was used to visualize and integrate all results provided by the Cuffdiff analysis. DAVID Bioinformatics Resources were used for gene annotation and pathway analysis.

4.5. Differential Expression Gene Validation by Real Time RT-PCR
----------------------------------------------------------------

Quantitative real-time PCR was performed to validate the differentially expressed genes identified by the Solexa sequencing data. Five differentially expressed genes were randomly selected for quantitative real-time PCR analysis. The Primer Premier 5.0 (PREMIER Biosoft International, Palo Alto, CA, USA) software was used to design the quantitative primers based on the cDNA sequence. RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) was used for RNA reverse transcription following the manufacturer's instructions, and DNase I and RNase-free (Thermo Fisher Scientific, Waltham, MA, USA) were used to treat the RNA sample to avoid genomic DNA contamination. The qPCR reaction was performed on a LightCycler 480 Real-Time PCR instrument (Roche, Penzberg, Germany) as follows: single cycle of denaturation at 95 °C for 5 min, 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 15 s and extension at 72 °C for 15 s. SYBR Green (BIO-RAD, Hercules, CA USA) was used for the qPCR reaction, and all reactions were performed in triplicate. The 2^−ΔΔ*C*t^ method was used to calculate the relative expression levels between transgenic and control mice, and all expression levels were normalized to the expression of 18S RNA. Significant differences between groups were assessed with a two-tailed *t*-test. The difference between groups was considered significant when *p* \< 0.05.

5. Conclusions
==============

In this study, gene expression profiles associated with hypertrophic skeletal muscle in myostatin propeptide transgenic mice were investigated by RNA sequencing. A total of 132 genes were identified and used for function annotation and gene enrichment analysis. The novel up-regulated genes were related to hypertrophic cardiomyopathy, focal adhesion, and PA signaling pathway, and ROS removal processes, suggesting that myostatin directly affects these processes during the regulation of skeletal muscle growth and mass. Two new signaling pathways, the Ky/Mybph/Actins and PA signaling pathways, were uncovered, which may account for myostatin propeptide-induced muscle hypertrophy. Our results provide information to help further understand how myostatin inhibition causes skeletal muscle hypertrophy.
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